There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teleflex Inc (TFX), Rocket Pharmaceuticals Inc (RCKT) and Dicerna Pharma (DRNA) with bullish sentiments.
Teleflex Inc (TFX)
Morgan Stanley analyst David Lewis maintained a Buy rating on Teleflex Inc today and set a price target of $315. The company’s shares closed yesterday at $290.15, close to its 52-week high of $290.42.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 11.6% and a 74.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Teleflex Inc has an analyst consensus of Strong Buy, with a price target consensus of $304.25, representing a 4.9% upside. In a report issued on February 21, Stephens also reiterated a Buy rating on the stock with a $300 price target.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals Inc (RCKT)
Cowen & Co. analyst Phil Nadeau initiated coverage with a Buy rating on Rocket Pharmaceuticals Inc today. The company’s shares closed yesterday at $16.61.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 7.7% and a 50.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Allogene Therapeutics Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals Inc with a $39 average price target, a 134.8% upside from current levels. In a report issued on February 19, Oppenheimer also assigned a Buy rating to the stock with a $39 price target.
Dicerna Pharma (DRNA)
Dicerna Pharma received a Buy rating from Cowen & Co. analyst Ritu Baral today. The company’s shares closed yesterday at $10.69.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.5% and a 50.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
